Trans Youth Deserve Access to Gender-Affirming Care
Trans youth deserve the same basic medical and ethical respect that any other young person deserves: care that is evidence-informed, developmentally appropriate, individually assessed, and guided by informed consent/assent and family support when possible.
Right now, political interference is increasingly getting in the way of trans youth accessing medically appropriate gender-affirming care. That interference is not abstract, and it is not temporary. Puberty is time-sensitive, and delaying or blocking evidence-based care can shape a young person’s body, mental health, and life trajectory in ways that may affect them permanently.
Youth and Gender-Affirming Care
Trans youth deserve the same thing any young person deserves: medical care that’s evidence-informed, individually assessed, and supervised by people who actually know what they’re doing. Political interference is getting in the way of that right now. Puberty is time-sensitive, and delaying care can shape a young person’s body and mental health in ways that don’t undo themselves.
What the research says
The peer-reviewed literature is on the side of access, not restriction. A few starting points:
- Supported trans kids do better. Olson et al. (2016), Pediatrics, found socially supported trans children showed developmentally normal depression and only minimal anxiety: pubmed.ncbi.nlm.nih.gov/26921285
- Access to care is protective. Tordoff et al. (2022), JAMA Network Open, found gender-affirming care was associated with lower odds of depression and suicidality over 12 months in trans and nonbinary youth: pubmed.ncbi.nlm.nih.gov/35212746
- Puberty suppression matters. Turban et al. (2020), Pediatrics, found access to pubertal suppression was associated with lower odds of lifelong suicidal ideation: pubmed.ncbi.nlm.nih.gov/31974216
- The standard of care itself. The Endocrine Society’s clinical practice guideline on endocrine treatment of gender-dysphoric/gender-incongruent persons: pubmed.ncbi.nlm.nih.gov/28945902
How to find research on a specific medication
These four are not exotic substances. They’re mainstream medicines, and searching for them on PubMed turns up decades of literature:
- Puberty blockers (GnRH agonists) — used for decades in pediatric care for precocious puberty, and in endometriosis, fibroids, and prostate cancer care. Search PubMed for “gonadotropin-releasing hormone agonists adolescents”.
- Spironolactone — a blood pressure and heart failure medication also used for acne. Search “spironolactone” for the general literature.
- Testosterone — standard endocrine treatment for hypogonadism. Search “testosterone therapy”.
- Estradiol — standard treatment for menopause symptoms and part of established clinical guidance. Search “estradiol therapy”.
How to search it yourself: go to pubmed.ncbi.nlm.nih.gov and type the drug name plus a word like adolescent or guideline. Look for papers from the last five years, and for titles containing “systematic review,” “meta-analysis,” or “clinical practice guideline” — those summarize many studies at once and carry the most weight. Anything marked “Free PMC article” is free to read in full. Click through to the abstract first; you usually don’t need to read the whole paper to know what it found.
The medications, in more detail
I’m not a physician, nurse practitioner, or pharmacist, and I don’t prescribe or manage medication. This is psychoeducation, not medical advice. Any medication decision happens with a licensed prescriber who can look at health history, labs, risks, and benefits. And to be explicit: I would never suggest anyone pursue “alternative routes” to prescription medications. Legal, medically supervised pathways only, with routine lab checks.
Puberty blockers (GnRH agonists)
GnRH agonists have been used in pediatric care for decades, most commonly for central precocious puberty (Endocrine Society overview: endocrine.org/patient-engagement/endocrine-library/precocious-puberty). They’re also used in endometriosis and uterine fibroids care (ACOG: acog.org/womens-health/faqs/endometriosis, acog.org/womens-health/faqs/uterine-fibroids) and in prostate cancer treatment (NCI: cancer.gov hormone therapy fact sheet). For puberty suppression, the purpose is to pause pubertal changes, giving a young person time to explore identity with support instead of being pushed through irreversible development that can intensify dysphoria (peer-reviewed overview in The Lancet Diabetes & Endocrinology: pubmed.ncbi.nlm.nih.gov/28793896).
Spironolactone
Spironolactone isn’t a puberty blocker and isn’t primarily a “trans medication.” It’s widely used in general medicine for high blood pressure, including resistant hypertension (Hypertension review: ahajournals.org/doi/10.1161/HYPERTENSIONAHA.120.15199) and heart failure (classic NEJM trial: nejm.org/doi/full/10.1056/NEJM199909023411001). It’s also used in dermatology for acne — a large randomized controlled trial in the BMJ (SAFA trial) found it significantly improved acne outcomes versus placebo (bmj.com/content/381/bmj-2022-074349). In gender-affirming care it may be used to reduce certain androgen-driven effects. Like any medication it has risks and needs oversight — potassium levels and kidney function in particular (Journal of the Endocrine Society: academic.oup.com/jes/article/6/11/bvac133/6696042; adolescent-focused data: pmc.ncbi.nlm.nih.gov/articles/PMC6553025).
Testosterone and estradiol
The hormones in gender-affirming care aren’t experimental substances. They’re mainstream medicines with established clinical guidance across many populations. Testosterone is standard treatment for hypogonadism (Endocrine Society guideline, 2018: academic.oup.com/jcem/article/103/5/1715/4939465). Estradiol is standard care for menopause symptoms (North American Menopause Society position statement, 2022: menopause.org position statement). The Endocrine Society’s gender-affirming hormone therapy guideline covers both in the gender-care context (academic.oup.com/jcem/article/102/11/3869/4157558). That these medications exist across mainstream medicine is part of why it’s misleading when public conversation treats gender-affirming care as uniquely dangerous.
Where clinical guidance lives:
- Endocrine Society, gender-affirming hormone therapy guideline: endocrine.org/clinical-practice-guidelines/gender-dysphoria-gender-incongruence
- American Academy of Pediatrics policy on care for transgender and gender-diverse youth (2018): pediatrics.aap.org
- WPATH Standards of Care, Version 8: wpath.org
Talk to a medical professional who cares
Research is for informing decisions, not making them alone. I’m a licensed counselor, not a physician, and I don’t prescribe or manage medication. What I can do is help you understand what the medications are and track how they are working for you in my notes, prepare good questions for your provider, and help you find a medical professional who is competent in and committed to gender-affirming care — an informed-consent clinic, an LGBTQ+ health center, or an endocrinology or family-medicine provider with experience in this area. If a provider is dismissive or political instead of clinical, you are allowed to walk out and find another one. A good prescriber will go over your health history, order labs, talk through risks and benefits, and keep monitoring you over time.